Xsensio raises CHF 4.2 million to expand development of proprietary platform and accelerate market launch

20.12.2021 15:41, Isabelle Mitchell

Xsensio, a company in the emerging field of wearable biosensing, has successfully completed a first close of its new financing round with Swiss and international investors to address the fast-growing market of wearable biosensing. Xsensio’s proprietary technology focuses on the continuous on-body monitoring of our health and wellbeing through wearable devices. Xsensio won Venture Kick in 2014 and was a TOP 100 Swiss Startup in 2015, 2017, and 2018. 

The investment round is led by Privilège Ventures, a Swiss venture capital firm with offices in Lugano, Zurich, and Boston, and included the EIC Fund and other international investors. The proceeds will be used to expand product and platform development, run clinical validation, and accelerate market launch through commercial partnerships in Europe and in the US.
 
Esmeralda Megally, co-founder and CEO of Xsensio: “The technology holds the potential for a paradigm shift in the way we deliver healthcare in the future, with a stronger focus on prevention through the use of minimally-invasive health monitoring devices. We are grateful to our company board and to our current and new investors for believing in our vision. We look forward to working with Privilège Ventures in this new phase of growth.”
 
Jacqueline Ruedin Rüsch of Privilège Ventures: “We believe the opportunity for wearable biosensing is massive, and the team has the ambition and the talent to address this opportunity. I’m really excited to start this journey with Xsensio.”